Human therapeutics represents the highest-value application in the
Genome Editing Techniques Market, with approved products and extensive clinical pipelines. Casgevy (exagamglogene autotemcel) became the first approved CRISPR therapy for sickle cell disease and transfusion-dependent beta-thalassemia in 2023-2024. Lyfgenia received approval for sickle cell disease using a different editing approach.
The
Genome Editing Techniques Market supports in vivo liver-directed therapies for transthyretin amyloidosis, hereditary angioedema, and cardiovascular disease. Oncology applications include engineered CAR-T cells with edited checkpoint receptors. Inherited retinal diseases, muscular dystrophies, and neurological disorders represent expanding therapeutic targets.
FAQ
Q: What approved CRISPR therapies exist? A: Casgevy for sickle cell and beta-thalassemia; Lyfgenia for sickle cell disease represent landmark approvals.
Q: How does ex vivo editing work? A: Patient cells are harvested, edited in laboratory conditions, expanded, and infused back as therapeutic products.
Q: What in vivo applications are in development? A: Liver-directed editing for transthyretin amyloidosis, PCSK9 cardiovascular targets, and hereditary angioedema lead development.
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
